Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD). The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Neurocrine Biosciences

Pharmaceutical

United States of America

The US pharmaceutical industry is a highly globalized industry, dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. The pharmaceutical industry is developing at an unusually rapid pace. The market for pharmaceuticals is growing persistently, and expenses for drugs will amount to $1.5 trillion globally by 2021. Together with Canada and Mexico, it represents the largest continental pharma market worldwide. Investments in biopharmaceutical innovation are driving contributions to the American economy and solidifying America’s role as a leader in medical innovation. The pharmaceuticals sector is forecasted to grow faster than any other market in the next five years with an emphasis on R&D.

Irvine

California

San Diego

201-500 Employees

Neurocrine Biosciences receives a solid overall rating of 4 out of 5 from anonymous employee reviews. Employees appreciate the positive work environment and the career development opportunities provided by the company. However, some employees mention concerns about management quality and work-life balance. Overall, employees seem to be satisfied with their experience at Neurocrine Biosciences.

Neurocrine Biosciences

#1 Video-Talent Marketplace

Ready to discover your perfect career?